Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

n of deferred

financing costs - 51 - 162

Amortization of premium

or discounts on

marketable securities 57 - 207 -

Impairment loss on

long-term investment 874 - 874 -

Non-cash financial expenses 30 - 107 -

Unrealized foreign exchange

loss (gain) (106) (74) 282 (547)

Future income tax (64) (35) (64) (71)

Stock-based compensation 674 492 3,573 1,857

-------------------------------------------------------------------------

(7,056) (3,497) (20,078) (14,023)

Net change in non-cash

operating items 1,008 (6,274) 1,116 (15,941)

-------------------------------------------------------------------------

(6,048) (9,771) (18,962) (29,964)

-------------------------------------------------------------------------

INVESTING ACTIVITIES

Acquisition of marketable

securities (11,733) (73,741) (64,980) (99,138)

Proceeds from disposals of

marketable securities 3,498 2,500 3,498 2,500

Proceeds from maturities

of marketable securities 15,491 4,585 81,876 20,499

Acquisition of property,

plant and equipment (454) (437) (1,600) (1,018)

Acquisition of intangible

assets (334) (25) (457) (690)

-------------------------------------------------------------------------

6,468 (67,118) 18,337 (77,847)

---------------------------------------------------
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...e/ -- During a memorial service in the Capitol Ro...d Lieutenant Governor Catherine Baker Knoll as a l...rvice, and a tireless advocate for the people of P...d lieutenant governor, Catherine was a noted and s...r family and her faith were driving forces in her ...
(Date:11/21/2008).../ -- The Generic,Pharmaceutical Association (GPhA...A President and CEO Kathleen Jaeger regarding the ...rging Health Care Competition and Consumer Issues....ng this roundtable demonstrates the,growing momen...safe and,affordable biogenerics sooner rather tha...
(Date:11/21/2008)...e to combat cancer, study says, , , F...hers have discovered that some cancer cells use la...t lead to new treatments that starve and kill thes...s in the body need to produce energy. They do this...es oxygen. Compared with normal cells, tumor cells...
(Date:11/21/2008)...enter.com, the premier site,for online nursing co...been,updated to improve the interactive experienc...ppincott Williams & Wilkins (LWW), NursingCent...uing education activities and free,access to 11,0...nals.,Lippincott Williams & Wilkins is a part...
Breaking Medicine News(10 mins):Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3Health News:GPhA Statement on FTC Roundtable on Biogenerics 2Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3
....S prescription use released last week revealed th...on// for Attention Deficiency Hyperactivity Disord...a similar prescription themselves. In the year 200...hildren and their parents were studied by research...
...versity study that used thermal imaging technology... rates has turned the conventional // wisdom that ...ead. “Comparing sexual arousal between men and wom...e in the amount of time it takes healthy young men...
...ry 523 children and adolescents in the United Stat...ding to estimates // from a major national study c...largest surveillance effort of diabetes among yout...n the United States, said Ronny A. Bell, Ph.D., M....
...rchers led by a team from the University of Virgin...hinovirus, // the cause of half of all colds, may ...ng an infectious gift for others who follow them. ... other forms of skin to skin contact can result in...
Other Medicine News:Health News:Thermal Imaging Shatters Arousal Gender Gap Myth 2Health News:One in 523 Children and Adolescents Have Diabetes 2Health News:One in 523 Children and Adolescents Have Diabetes 3Health News:Hotel Guests Often Leave Their Cold Behind 2
(Date:11/20/2008)...., Nov. 20 Radius Health ("Radius"... $15 million to its second institutional financing...2.5 million and the total amount raised since the ...g institutional investors participated in the fina...cluding MPM Capital, The Wellcome Trust, HealthCar...
(Date:11/19/2008)...Calif., Nov. 19 Amgen,(...gy Company, a subsidiary of,Takeda Pharmaceutical...,enrollment in the Phase 3 MONET1 trial evaluatin...xel and carboplatin for the first-line treatment o... been temporarily suspended,following a planned s...
(Date:11/19/2008)...llion Payment from Roche- , , MONTVALE, N.J...ceuticals Corp. (Nasdaq: MEMY ) today announced ...hase 2 trial of R3487/MEM 3454, its lead alpha-7 n... associated with schizophrenia (CIAS). The Compan..., triggering a $5.0 million payment from its partn...
(Date:11/18/2008)...ssociation,s 2008 Faces of Influenza survey unders...against influenza; Mother and Gold Medalist Kristi..., Nov. 18 While 78 percent of moth...re and potentially life-threatening disease that c... families will get vaccinated this season, accordi...
Breaking Medicine Technology:Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6InkSure and AuthentiForm Announce Assignment of Patent Portfolio 10261 1InkSure and AuthentiForm Announce Assignment of Patent Portfolio 10261 2InkSure and AuthentiForm Announce Assignment of Patent Portfolio 10261 3ActivBiotics Completes Sale of Fixed Assets 3B Expands Due Diligence Initiative for the Sale of Intellectual Property Including Drug Product Candidat 2778 1BioMarin Appoints Dr Gordon Vehar Vice President of Research 2777 1BioMarin Appoints Dr Gordon Vehar Vice President of Research 2777 2BioMarin Appoints Dr Gordon Vehar Vice President of Research 2777 3Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2776 1Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2776 2Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2776 3
...ESS WIRE)--May 8, 2007 - AVANIR,Pharmaceuticals (N...efficacy, safety and improvements in patient-cente...neuropathic (DPN) pain treated,with the investigat...e) will be presented in two scientific posters at ...ain, being held in,Berlin, Germany on June 7 to 10...
...RE)--May 9, 2007 - Results of a Phase 2a,clinical ...d,amikacin) to treat hospital acquired gram-negati...erican Thoracic Society (ATS),International Confer... Dr. Michael S. Niederman, MD, Chairman, Depar...Hospital, Professor of, Medicine; Vice C...
Other Medicine Technology:AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 4Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 2Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 3
Kaye Skin Hook, Single Prong
Designated most popular model or size.
Large deep curve.
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl
Medicine Products: